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Abstract
Background: Numerous studies conducted over the past 30 years have pointed to the presence of Epstein–Barr
virus (EBV) in gastric cancer samples. This study was aimed to provide a meta-analytic review of the prevalence of
EBV in gastric cancer patients, and to clarify the relationship between EBV infection and gastric cancer.
Methods: A literature search was performed electronically using online databases for English language publications
until July 1, 2019. The pooled EBV prevalence and 95% confidence intervals (CIs) were estimated using a random-
effects model. To determine the association between EBV and gastric cancer, pooled odds ratio (OR) and its 95% CI
were computed for case-control studies. Two separate analyses were performed on data from case-control studies
with matched and non-match pairs designs to calculate the pooled estimates of ORs.
Results: The pooled prevalence of EBV in 20,361 gastric cancer patients was 8.77% (95% CI: 7.73–9.92%; I2 = 83.2%).
There were 20 studies with matched pairs design, including tumor and tumor-adjacent normal tissue pairs from
4116 gastric cancer patients. The pooled ORs were 18.56 (95% CI: 15.68–21.97; I2 = 55.4%) for studies with matched
pairs design and 3.31 (95% CI: 0.95–11.54; I2 = 55.0%) for studies with non-matched pairs design. The proportion of
EBV-associated gastric cancer among male cases was significantly higher than among female cases (10.83%, vs.
5.72%) (P < 0.0001). However, the pooled OR estimate for EBV-associated gastric cancer was significantly higher
among females (21.47; 95% CI: 15.55–29.63; I2 = 0%) than in males (14.07; 95% CI: 10.46–18.93; I2 = 49.0%) (P = 0.06).
EBV was more prevalent in the cardia (12.47%) and the body (11.68%) compared to the antrum (6.29%) (P = 0.0002).
Conclusions: EBV infection is associated with more than 18 times increase the risk of gastric cancer. Although the
prevalence of EBV was higher in male patients than in female patients with gastric cancer, women are more likely
than men to develop EBV-associated gastric cancer. Our findings showed that using tumor-adjacent normal tissues
as the control group provides more robust and accurate results regarding the relationship between EBV infection
and gastric cancer.
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Background
According to GLOBOCAN statistics in 2018, gastric
cancer is the fifth most frequently diagnosed cancer
and the third leading cause of cancer-related mortality
in the world accounted for 8.2% of all cancer deaths.
Over 1,000,000 new cases of gastric cancer diagnosed
in 2018 around the world, with an estimated 783,000
deaths [1]. Gastric cancer arises from a combination
of multiple environmental and genetic risk factors,
and infectious agents are one of the critical environ-
mental factors which contribute to an increased risk
of developing several malignancies [2].
Epstein-Barr virus (EBV), as a member of the Herpes-
viridae family, is the first described human cancer virus
and is responsible for approximately 1.8% of all human
cancers, including Hodgkin lymphoma, Burkitt lymph-
oma, NK/T cell lymphoma, and nasopharyngeal carcin-
oma [3]. However, the role of EBV in the development
of other malignancies is still under investigation. At the
beginning of the 1990s, the association between EBV
and gastric carcinomas was found. The first report was
made by Burke et al. in a case of lymphoepithelial-like
gastric carcinoma [4], and afterwards, the association
was observed in gastric adenocarcinoma [5]. Subse-
quently, numerous studies demonstrated an essential
role of EBV in gastric carcinogenesis.
To date, the mechanisms of EBV-associated gastric
cancer are still not comprehensively clarified. Generally,
virologic aspects, in conjunction with host genome
abnormalities, co-potentiate the cancer progression. Re-
garding the virologic background, the EBV genome en-
codes oncoproteins, which target important cellular
pathways. EBV-associated gastric cancer belongs to
latency type I infection, in which only EBNA1, EBER,
BamHI A rightward transcript (BART), and BART miR-
NAs are highly expressed, while the latent membrane
protein 2A (LMP2A) can be detected in 40% of cases
[6]. Evidence suggests that latent infection by EBV and
the expression of the EBV latent genes lead to the host
genome abnormalities like aberrant DNA methylation,
which has attracted more attention in recent years [7].
The gold standard for the diagnosis of EBV infection
in histopathologic samples is ISH, which detects EBV-
encoded small RNA-1 (EBER1). EBER1 is highly
expressed in latently EBV-infected cells (up to 107 copies
per cell) [8]. EBER1 signals are commonly identified in
the nuclei of nearly all carcinoma cells in EBV-
associated gastric carcinoma [9]. PCR-based methods are
also widely used for the diagnosis of EBV infection.
Although PCR is a cost-efficient and simple technique
for the detection of EBV infection, it is prone to false-
positive results due to its low specificity. The low specifi-
city of PCR can be explained by the fact that memory
cells and/or non-tumor, bystander lymphocytes may also
be investigated for the presence of the EBV genome.
Therefore, PCR-based methods are more sensitive but
less specific than the gold standard ISH method to
detect EBV [10, 11].
There are several published meta-analyses addressing
the prevalence of EBV among gastric cancer patients
[12–16], however, their results are out of date and only
descriptive. On the other hand, they did not perform
any analysis to estimate the association between the
EBV and gastric cancer risk. The last meta-analysis
conducted by Bae et al. focused on the results of case-
control studies published up to 2014 to prove the rela-
tionship between EBV and gastric cancer for the first
time [17]. However, some important variables such as
gender, type of samples, and tumor anatomical location
did not include in their meta-analysis. Our meta-
analysis aims to determine the association of EBV infec-
tion with gastric cancer and to provide an updated
pooled prevalence of EBV infection among gastric can-
cer patients. It is anticipated that the results of the
present study will direct future experimental studies to-
ward elucidating the role of EBV infection in the car-
cinogenesis of gastric cancer, and will inform clinicians
and policy-makers to improve preventive intervention
and control.
Methods
The present systematic review and meta-analysis was
performed according to the recommendations of the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [18].
Search strategy
A rigorous literature search was conducted using
PubMed, Web of Science, Scopus, EMBASE, and Google
scholar to identify all published articles reporting the
prevalence of EBV in patients with gastric cancer. Data-
bases were searched from inception to July 1, 2019. The
bibliographies of all articles obtained were also reviewed
for additional relevant publications. The list of keywords
used for this systematic review and meta-analysis is pro-
vided in Additional file 1.
Study selection
All records were imported to EndNote software version
X8 (Thomson Reuters, California, USA), and duplicate
entries were removed. The screening of the title and
abstract of the remaining records was independently
conducted by two researchers. The full-texts of the
remaining records were then retrieved and reviewed,
and any disagreements were resolved through discussion
by a third investigator.
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Eligibility criteria
Studies were considered eligible for inclusion in the
present meta-analysis, if they met the following
criteria: (1) Studies using cross-sectional and case-
control designs reporting the prevalence of EBV
infection in patients with different types of gastric
carcinoma; (2) Studies using EBER-ISH technique to
detect the presence of EBV transcripts or nucleic
acids; (3) Studies using the formalin-fixed paraffin-
embedded (FFPE) tissues and biopsies samples; (4)
Studies published in peer-reviewed journals in the
English language.
Studies with following characteristics were excluded
from the present meta-analysis: (1) Studies using sero-
logical techniques such as enzyme-linked immunosorb-
ent assay (ELISA) to detect circulating antibodies to
EBV infection; (2) Studies evaluating the presence of
EBV in serum, plasma or peripheral blood mononuclear
cell (PBMC) samples; (3) Studies assessing the presence
of EBV in gastric carcinoma patients with underlying
disorders; (4) Studies evaluating the presence of EBV by
molecular methods such as PCR, nested-PCR and Real-
Time PCR; (5) Studies addressing remnant gastric
cancer, gastric lymphoma, and other types of gastric
malignancies; (6) Studies using techniques other than
EBER-ISH, (7) Studies published in languages other
than English; (8) Reviews, letters to the editor,
abstracts, and case reports.
Data extraction and quality assessment
Two investigators independently extracted data from
all eligible studies in a pre-designed data extraction
form using Microsoft Excel 2013 (Microsoft Corpor-
ation, Redmond, Washington, USA). The two investi-
gators cross-checked each other’s data extraction, and
any disagreements were resolved by a third investiga-
tor. After retrieving the eligible articles, a modified
checklist based on the guidelines of the strengthening
the reporting of observational studies in epidemiology
(STROBE) was used for assessing the risk of bias of
the included studies [19, 20]. The checklist includes
12 questions that cover different methodological
aspects. According to the checklist, the highest score
was 12, representing the highest quality, and the
minimum acceptable score was 8. Lastly, studies
Fig. 1 Flowchart presenting the steps of literature search and selection
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Table 1 Characteristics of the included studies in this systematic review and meta-analysis










Rowlands [29] 1993 UK and Japan Cross-sectional FFPE 174 9
Shibata [30] 1993 USA Cross-sectional FFPE 187 19
Tokunaga [31] 1993 Japan Cross-sectional FFPE 1848 122
Tokunaga [32] 1993 Japan Cross-sectional FFPE 999 69
Imai [33] 1994 Japan Case-control FFPE 1000 1000 70 0
Ott [34] 1994 Germany Case-control FFPE 39 39 7 0
Shousha [35] 1994 UK Case-control FFPE 19 9 1 5
Yuen [36] 1994 China Case-control FFPE 74 36 7 0
Harn [37] 1995 Taiwan Case-control FFPE 55 49 6 0
Gulley [38] 1996 USA Case-control FFPE 95 95 11 0
Moritani [39] 1996 Japan Case-control FFPE 132 132 15 0
Selves [40] 1996 France Case-control FFPE 59 59 5 0
Shin [41] 1996 South Korea Case-control FFPE 89 37 12 0
Galetsky [42] 1997 Russia Case-control FFPE 206 206 18 0
Clark [43] 1997 Singapore Cross-sectional FFPE 137 6
Ojima [44] 1997 Japan Cross-sectional FFPE 412 83
Yanai [45] 1997 Japan Cross-sectional FFPE 124 12
Herrera-Goepfert [46] 1999 Mexico Cross-sectional FFPE 135 11
Kume [47] 1999 Japan Case-control FFPE 344 344 40 0
Takano [48] 1999 Japan Cross-sectional FFPE 513 33
Wan [49] 1999 China Case-control FFPE 58 58 6 0
Chapel [50] 2000 France Case-control FFPE 56 56 7 0
Wu [51] 2000 Taiwan Cross-sectional Biopsy 150 30
Corvalan [52] 2001 Chile Case-control FFPE 185 185 31 0
Kijima [53] 2001 Japan Cross-sectional FFPE 313 23
Ishii [54] 2001 Japan Cross-sectional FFPE 119 23
Koriyama [55] 2001 Brazil Cross-sectional FFPE 300 24
Luqmani [56] 2001 UK Case-control FFPE 20 79 1 9
Burgess [57] 2002 UK Cross-sectional FFPE 534 9
Kang [58] 2002 South Korea Cross-sectional FFPE 233 21
Kattoor [59] 2002 India and Japan Cross-sectional FFPE 2226 135
Vo [60] 2002 USA Cross-sectional FFPE 107 11
Czopek [61] 2003 Poland Cross-sectional FFPE 40 5
Oda [62] 2003 Japan Case-control FFPE 97 97 5 0
Ishii [63] 2004 Japan Case-control FFPE 133 133 19 0
Lee [64] 2004 South Korea Cross-sectional FFPE 1127 63
Lopes [65] 2004 Brazil Case-control FFPE 53 53 6 0
van Beek [66] 2004 Netherlands Cross-sectional FFPE 566 41
Alipov [67] 2005 Kazakhstan Case-control FFPE 139 139 14 0
Herrera-Goepfert [68] 2005 Mexico Case-control FFPE 330 330 24 2
Luo [69] 2005 China Case-control FFPE 172 172 11 0
Yoshiwara [70] 2005 Peru Cross-sectional FFPE 254 10
Campos [71] 2006 Colombia Cross-sectional FFPE 368 42
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obtained the minimum score, and more were consid-
ered eligible to include in the main meta-analysis.
The following characters were extracted from each
study: first author’s name, publication date, study
location, study design, sample size, sex, type of speci-
men, histological type, number of EBV-positive sam-
ples, tumor anatomical location, depth of invasion,
tumor stage, and lymph node invasion.
Statistical analysis
The present meta-analysis had two primary purposes; first,
providing an updated estimate of the pooled prevalence of
EBV among patients with gastric cancer, and secondly, in-
vestigating the association between EBV and the develop-
ment of gastric cancer. A random-effect meta-analysis
using the inverse variance method was applied to estimate
the pooled prevalence of EBV (DerSimonian-Laird method)
[21]. The logit transformation was used for stabilizing the
variance and data normalization, and the Clopper-Pearson
method was applied to determine the 95% confidence inter-
vals (CIs) for proportions [22].
To evaluate the strength of the association between
EBV infection and gastric cancer risk, the pooled odds
ratios (ORs) with 95% CIs were generated from a
random-effects model based on the DerSimonian-Laird
method. For studies with a zero cell, a continuity correc-
tion of 0.5 was applied. We also conducted subgroup
analyses to identify the possible sources of heterogeneity.
The heterogeneity among the studies was assessed
through I2 statistics [23]. To explore potential publica-
tion bias and symmetric assumption among the included
studies, a Begg’s funnel plot was constructed [24]. All
Table 1 Characteristics of the included studies in this systematic review and meta-analysis (Continued)










Szkaradkiewicz [72] 2006 Poland Cross-sectional FFPE 32 14
Luo [73] 2006 China Cross-sectional FFPE 185 13
von Rahden [74] 2006 Germany Case-control FFPE 82 82 5 0
Abdirad [75] 2007 Iran Cross-sectional FFPE 273 9
Jung [76] 2007 South Korea Cross-sectional FFPE 111 7
Lima [77] 2008 Brazil Cross-sectional FFPE 71 6
Ryan [78] 2009 USA Cross-sectional FFPE 113 11
Trimeche [79] 2009 Tunisia Cross-sectional FFPE 96 4
Truong [80] 2009 USA Case-control FFPE 235 72 12 0
Ferrasi [81] 2010 Brazil Case-control FFPE 54 54 5 0
Koriyama [82] 2010 Japan Cross-sectional FFPE 156 21
Chen [83] 2010 China Case-control FFPE 676 676 45 3
Boysen [84] 2011 Denmark Cross-sectional FFPE 131 10
BenAyed-Guerfali [2] 2011 Tunisia Cross-sectional FFPE 81 12
de Lima [85] 2012 Brazil Cross-sectional FFPE 160 11
Ksiaa [86] 2014 Tunisia Cross-sectional FFPE 43 4
Aslane [87] 2016 Algeria Case-control FFPE 97 10 22 0
Tsai [88] 2016 Taiwan Cross-sectional FFPE 1039 52
Zhang [89] 2016 China Cross-sectional FFPE 600 30
Liu [90] 2016 China Case-control FFPE 206 206 15 0
Na [91] 2017 South Korea Cross-sectional FFPE 205 15
Boger [92] 2017 Germany Cross-sectional FFPE 484 22
Kim [93] 2017 South Korea Case-control FFPE 207 56 13 0
Nogueira [94] 2017 Portugal Case-control FFPE 82 33 9 1
Ribeiro [3] 2017 Portugal Cross-sectional FFPE 179 15
de Souza [95] 2018 Brazil Cross-sectional Biopsy 302 62
Wanvimonsuk [96] 2018 Thailand Case-control FFPE 33 55 4 0
Martinez-Ciarpaglini [97] 2019 Spain Cross-sectional FFPE 209 13
FFPE Formalin-Fixed Paraffin-Embedded
Tavakoli et al. BMC Cancer          (2020) 20:493 Page 5 of 14
the above-mentioned analyses were conducted using the
R package “meta” (version 3.5.3 [2019-03-11]) [25, 26],
and P values less than 0.05 were considered statistically
significant. Furthermore, for each case-control study
with matched pairs design, we separately computed
matched-pairs OR and its corresponding variance using
the “escalc” function in the R “metafor” package [27]
(version 2.1–0 [2019-05-13]. The obtained results were
then used for performing meta-analysis to calculate the
matched pairs pooled OR.
Results
Literature selection
The electronic database searches were identified 597
articles, and additional 14 relevant records were found
through bibliographic hand searching. Of these 611 arti-
cles, 151 duplicates were excluded, so a total of 460 arti-
cles was screened according to their title and abstract. A
total of 353 articles was eliminated after reading the title
and abstract due to apparent irrelevance. The remaining
107 articles were assessed for agreement with the inclu-
sion and exclusion criteria by the full-text review, and 72
papers met the scope criteria. Based on the modified
STROBE checklist, 71 papers were deemed to have good
quality (obtained scores of 8 and above), and only one
paper [28] was failed to reach score 8. Finally, 71 papers
were included in this systematic review and meta-
analysis. Figure 1 shows the process of literature retrieval
and screening using a flow chart.
Study characteristics
Table 1 shows the characteristics of eligible studies
included in the systematic review and meta-analysis. Out
of 71 studies, 30 were case-control, and 41 were cross-
sectional in design. Publication dates ranged from 1993
to 2019, and over half of the studies (59.1%) described
specimens recruited before 2005. Among the studies
included in this meta-analysis, four were from Africa, 16
were from America, 35 were from Asia, and 17 were
from Europe. Of the 72 studies included, 46 provided
information on patients’ sex, 40 studies provided data on
histological type, and 35 had data on tumor anatomical
location. The most extensive study included 2226 gastric
cancer cases, and the smallest covered 19 cases. Most
studies were from Japan (n = 15).
The prevalence of EBV among gastric cancer patients
The first aim of the current study was to determine the
pooled prevalence of EBV in 20,361 gastric cancer
patients from 26 countries, and the range was from 1.69
to 43.75% of the selected individual studies. Figure 2
shows the prevalence of EBV and 95% CI estimates from
individual studies according to the random-effects
model. The pooled prevalence of EBV among gastric
cancer patients was 8.77% (95% CI: 7.73–9.92%; I2 =
83.2%). The highest and lowest prevalence of EBV were
found in gastric cancer patients from Poland and the
United Kingdom, respectively (25.57, 95%CI: 6.13–
64.36% vs. 2.78, 95%CI: 1.51–5.06%). The proportion of
EBV-positive gastric cancer among male cases was sig-
nificantly higher than among female cases (10.83, 95%CI:
9.43–12.40% vs 5.72, 95%CI: 4.27–7.64%) (P < 0.0001)
(Fig. 3). Table 2 presents more detailed information on
the prevalence of EBV infection in gastric cancer
patients for subgroups.
Fig. 2 Forest plot of the prevalence of EBV infection among gastric
cancer patients, according to the random effect model
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The association between EBV and gastric cancer
Among 30 case-control studies, 20 had matched pairs
design, including tumor and tumor-adjacent normal tis-
sue pairs from 4116 gastric cancer patients. The
remaining ten non-matched case-control studies in-
cluded 911 cases of gastric cancer and 436 controls.
Using data obtained from studies with non-matched
pairs design, the pooled OR of EBV infection was 3.31
(95% CI: 0.95–11.54; I2 = 55.0%), whereas the pooled OR
for studies with matched pairs design was 18.56 (95% CI:
15.68–21.97; I2 = 55.4%), indicating a solid significant
positive relationship between EBV infection and gastric
cancer (Fig. 4). So, we further performed a subgroup
analysis for studies with matched pairs design. Table 3
presents details on the association between EBV infec-
tion and gastric cancer risk for subgroups. Finally, the
analysis of the funnel plot did not show evidence of
asymmetry (Fig. 5), and Begg’s test indicated an absence
of publication bias among all the studies included in this
meta-analysis (P = 0.18).
Discussion
Our meta-analysis showed that the pooled prevalence
of EBV among gastric cancer patients from 26 coun-
tries is 8.77% (95% CI: 7.73–9.92%; I2 = 83.2%). We
chose strict inclusion and exclusion criteria to obtain
pertinent studies and to increase the chance of find-
ing a valid conclusion. The pooled prevalence and OR
obtained in this meta-analysis were calculated from
studies that detected EBV infection with the ISH
method. All studies that investigated the presence of
EBV by other methods, including different types of
PCR assays, and even immunohistochemistry (IHC),
did not consider in our analysis. The reason for this
stems from the fact that the sensitivity and specificity
Fig. 3 Forest plot of the prevalence of EBV infection among gastric cancer patients, according to the random effect model in females (a) and
males (b)
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of each detection method are different, and it is not
reliable to draw a conclusion using the pooled data.
The gold standard technique for the detection of EBV
in tissues is ISH with EBV EBERs (EBER-ISH) due to its
high sensitivity and specificity to determine the precise
intranuclear localization of the EBV-infected cells. The
diagnosis of EBV-associated gastric cancer is confirmed
by the presence of EBER within the tumor cells and its
absence in the normal tissue adjacent to the tumor [3].
Many studies have reported the higher prevalence of
EBV among gastric cancer patients by PCR assay than
the EBER-ISH technique [17]. However, PCR is unable
to discriminate between cancer cells and lymphocytes
infiltrating in tumor stromal, and thus it is impossible to
know from where the EBV genome is amplified. It
should be noted that the vast majority of people (nearly
90%) are EBV carriers, and their lymphocytes probably
contain EBV genomes [11]. Regarding the statements
above, our meta-analysis exclusively focused on the posi-
tivity of the EBV-associated gastric cancers by ISH only.
One of the major strong points in this meta-analysis is
that the pooled estimates of ORs were calculated from
studies with matched pairs and non-matched pairs
designs, separately, with different statistical methods.
The detailed descriptions about the analysis of data for
matched pairs and non-matched pairs studies are avail-
able in several previous studies [98]. It has been recom-
mended that a matched-pairs analysis should be used to
assess effect sizes for studies with matched pairs design.
Accordingly, the pooled OR determined for studies with
non-matched pairs and matched pairs designs were 3.31
(95% CI: 0.95–11.54; I2 = 55.0%) and 18.56 (95% CI:
15.68–21.97; I2 = 55.4%), respectively. We performed two
separate analyses for studies with match pairs and non-
Table 2 Subgroup analysis of the prevalence of EBV infection in gastric cancer patients










Overall – 71 8.77 (7.73–9.92) 83.2%, P < 0.01 –
Study design Cross-sectional 41 8.22 (6.90–9.77) 88.2%, P < 0.01 P = 0.15
Case-control 30 9.71 (8.32–11.30) 59.4%, P < 0.01
Publication date ≤2005 42 8.91 (7.65–10.35) 82.5%, P < 0.01 P = 0.77
> 2005 29 8.56 (6.81–10.71) 84.6%, P < 0.01
Sex Male 46 10.83 (9.43–12.40) 73.2%, P < 0.01 P < 0.0001†
Female 46 5.72 (4.27–7.64) 74.9%, P < 0.01
Study location Africa 4 11.93 (5.97–22.44) 76.8%, P < 0.01 P = 0.64
America 16 9.51 (7.45–12.07) 76.8%, P < 0.01
Asia 35 8.38 (7.15–9.80) 84.1%, P < 0.01
Europe 17 8.21 (5.82–11.46) 80.4%, P < 0.01
Development status Developed countries 34 8.42 (7.11–9.94) 82.1%, P < 0.01 P = 0.64
Developing countries 39 8.92 (7.40–10.73) 83.5%, P < 0.01
Sample type FFPE 69 8.49 (7.54–9.55) 79.9%, P < 0.01 P < 0.0001†
Biopsy 2 20.36 (16.89–24.32) 0%, P = 0.9
Lauren’s histological type Intestinal type 40 8.10 (6.64–9.83) 69.2%, P < 0.01 P = 0.31
Diffuse type 40 9.41 (7.54–11.69) 77.0%, P < 0.01
Tumor anatomical location Cardia 32 12.47 (10.39–14.89) 24.8%, P = 0.1 P = 0.0002†
Body 32 11.68 (9.96–13.65) 32.0%, P = 0.04
Antrum 35 6.29 (4.67–8.42) 76.8%, P < 0.01
Depth of invasion Early 7 13.00 (9.20–18.06) 0%, P = 0.71 P = 0.45
Advanced 7 10.80 (7.64–15.06) 58.1%, P = 0.03
Tumor stage I + II 14 7.39 (5.79–9.39) 29.5%, P = 0.14 P = 0.36
III + IV 14 8.80 (6.57–11.68) 64.4%, P < 0.01
Lymph node invasion Absent 14 8.75 (6.02–12.55) 57.9%, P < 0.01 P = 0.91
Present 14 9.00 (6.33–12.65) 77.4%, P < 0.01
FFPE Formalin-Fixed Paraffin-Embedded
†Statistically significant
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match pairs designs to demonstrate that the strength of
association (ORs) between EBV infection and gastric
cancer is the highest when tumor-adjacent normal tis-
sues are used as a control group. This is due to the fact
that confounding variables are eliminated from data ana-
lysis. Therefore, we can obtain more accurate and robust
estimates of the association between EBV and gastric
cancer. This finding of our study will be beneficial for
researchers to design their future case-control studies
appropriately. Using the tumor-adjacent normal tissues
as the control group will provide more accurate results
regarding the relationship between EBV infection and
gastric cancer.
To date, several studies have attempted to discover
the role of EBV infection in gastric cancer progres-
sion. EBV enters B lymphocytes in oropharyngeal
lymphoid tissues. The virus then enters the gastric
epithelial cells, either by the cell-to-cell contact be-
tween B lymphocytes and gastric epithelial cells or by
direct entry into the gastric epithelia [99]. It has been
reported that EBV entry into the gastric epithelial
cells is facilitated by the previous mucosal damage
[68]. After the virus enters the cell, EBV establishes
type I latency in which a limited set of the latent
gene is expressed [79]. A recent systematic review
study showed that the most of the EBV latent pro-
teins expressed in gastric cancer cases were EBNA1
(98.1%) and LMP2A (53.8%), whereas LMP1 and
LMP2B were detected in only 10% of EBV-associated
gastric cancer cases. Some of the lytic proteins, such
as BARF1, were also reported to be present in almost
half of EBV-associated gastric cancer cases [100]. It is
Fig. 4 Forest plot of the association between EBV infection and gastric cancer risk (according to random effect model) in studies with match
pairs design (a) and non-match pairs design (b)
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shown that the EBV-encoded BARF1 acts as an onco-
gene and promotes cell proliferation in gastric cancer
through upregulation of NF-κB signaling and reduc-
tion of the cell cycle inhibitor p21 [101]. It is well
known that DNA methylation plays a crucial role in
gastric cancer development and progression [102].
Methylation of both viral and cellular genome is one of the
critical mechanisms involved in the development and main-
tenance of EBV-associated gastric cancer. It is well docu-
mented that EBV latent membrane protein 2A (LMP2A)
plays a variety of key roles in the epigenetic abnormalities
such as aberrant DNA methylation in host stomach cells,
and the development and maintenance of EBV-associated
gastric cancer [9].
Another interesting finding of our meta-analysis is that
the prevalence of EBV was 1.9-fold higher in male
patients than in female patients with gastric cancer (P <
0.0001). However, the OR estimate for EBV-associated
gastric cancer was significantly higher among females
than in males (P = 0.06). According to these results, we
concluded that women are more likely than men (1.5-
fold) to develop EBV-associated gastric cancer. This
novel finding can be explained by different genetic back-
grounds, lifestyles, or hormonal conditions between the
two genders.
Subgroup analyses based on the tumor anatomical lo-
cation indicate an anatomic preference for EBV during
gastric carcinogenesis. Indeed, EBV-associated gastric
cancers were significantly more prevalent in the cardia
and the body of the stomach than in the antrum (P =
0.0002) (Table 2). However, the situation was different
when OR was calculated. So that the OR estimate for
EBV-associated gastric cancer was remarkably higher in
the antrum than in the cardia and in the body (Table 3),
although the difference was not statistically significant.
This feature can be justified by the fact that the various
parts of the stomach have different physiological
conditions.
One prominent finding of the present meta-analysis is
that EBV was detected more frequently in biopsy sam-
ples than in FFPE specimens from gastric cancer patients
(2.4-fold, P < 0.0001). It is well documented that there
are several challenges when working with FFPE samples,
such as the low amount of extracted nucleic acids, and
fragmentation of genomes and transcripts during the
processes of fixation and embedding in paraffin. There-
fore, to prevent false-negative results, using biopsy sam-
ples is recommended.
According to Lauren’s histological classification, gastric
carcinoma is classified into two distinct types, namely
Table 3 Subgroup analysis of association between EBV infection and gastric cancer risk
Characteristics Categories No. of
Studies
Pooled OR (95% CI) Heterogeneity
test
I2%, p-value
Differences between subgroups; χ2
test
(p-value)
Overall – 20 18.56 (15.68–21.97) 55.4%, P < 0.01 –
Sex Male 8 14.07 (10.46–18.93) 49.0%, P = 0.06 P = 0.06
Female 8 21.47 (15.55–29.63) 0%, P = 0.55
Study location America 5 15.69 (10.82–22.74) 57.4%, P = 0.05 P = 0.33
Asia 9 21.00 (16.77–26.30) 59.1%, P = 0.01
Europe 6 17.23 (13.19–22.51) 5.6%, P = 0.38
Development status Developed countries 10 17.31 (13.38–22.40) 58.7%, P < 0.01 P = 0.46
Developing
countries
10 19.73 (15.56–25.03) 56.2%, P = 0.01
Lauren’s histological type Intestinal type 10 15.07 (9.55–23.78) 62.0%, P < 0.01 P = 0.27
Diffuse type 10 10.69 (7.14–16.00) 79.0%, P < 0.01
Tumor anatomical
location
Cardia 10 6.65 (5.18–8.52) 21.8%, P = 0.24 P = 0.46
Body 10 6.31 (2.38–16.69) 97.0%, P < 0.01
Antrum 11 15.55 (4.12–58.62) 98.2%, P < 0.01
Depth of invasion Early 3 5.87 (2.78–12.40) 45.8%, P = 0.16 P < 0.01†
Advanced 3 19.94 (13.31–29.85) 22.9%, P = 0.27
Tumor stage I + II 2 33.50 (10.85–
103.46)
73.8%, P = 0.05 P = 0.52
III + IV 2 22.26 (13.05–37.96) 24.6%, P = 0.25
Lymph node invasion Absent 3 16.98 (9.02–31.95) 1.3%, P = 0.36 P = 0.58
Present 3 23.21 (9.44–57.03) 80.6%, P < 0.01
† Statistically significant
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intestinal and diffuse types. There are many differences
between intestinal and diffuse types based on their epi-
demiology, etiology, and pathology [82]. However, the
current meta-analysis showed that the prevalence of EBV
was similar in intestinal and diffuse types (8.10 and 9.41%,
respectively), and no significant association of EBV infec-
tion with the histological type was found (P = 0.31).
Similarly, our results did not indicate any significant dif-
ference in the prevalence of EBV-associated gastric cancer
among different geographic regions, even between devel-
oped and developing countries. The same prevalence in
developed and developing countries demonstrates that
economic conditions are not related to EBV-associated
gastric cancer risk.
There are some limitations in this study arose from
the nature of the data sources used in the meta-analysis.
Gastric cancer is a multifactorial disease affected by sev-
eral risk factors. Age is considered as a risk factor for
the development of EBV-associated gastric carcinoma.
However, the majority of studies included in the current
meta-analysis did not categorize EBV-infected and -un-
infected gastric cancer patients based on the age group.
Subsequently, we were not able to perform a subgroup
analysis in this regard. Besides, there are some reports
on the association between Helicobacter pylori infection
and gastric cancer. Nevertheless, we did not consider
data regarding the co-infection of EBV and Helicobacter
pylori.
Conclusions
To sum up, our meta-analysis suggests that the pooled
prevalence of EBV among patients with gastric cancer
was 8.77%. To determine the association between EBV
infection and gastric cancer, a matched-pairs analysis
from case-control studies was performed, and the pooled
OR was calculated 18.56. This finding indicates a robust
positive association between EBV infection and gastric
cancer risk. We recommend using biopsy instead of
FFPE samples and the ISH technique instead of PCR
methods to ensure the validity of results.
Furthermore, the pooled prevalence of EBV was
obtained from data from 26 countries in the world.
Therefore, conducting studies in other geographical
regions is strongly recommended to get more reliable es-
timates. Furthermore, we suggest that researchers use
the tumor-adjacent normal tissues as the control group
for their case-control studies to achieve more accurate
results regarding the relationship between EBV infection
and gastric cancer.
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